BioMarin

YTD

ALL

Trade BioMarin 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMRN

BioMarin Pharmaceutical, Inc. is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline.

CEO

Alexander Hardy

CEOAlexander Hardy

Employees

3,221

Employees3,221

Headquarters

San Rafael, California

HeadquartersSan Rafael, California

Founded

1997

Founded1997

Employees

3,221

Employees3,221

BMRN Key Statistics

Market cap

11.52B

Market cap11.52B

Price-Earnings ratio

43.78

Price-Earnings ratio43.78

Dividend yield

—

Dividend yield—

Average volume

1.42M

Average volume1.42M

High today

$60.64

High today$60.64

Low today

$59.40

Low today$59.40

Open price

$59.59

Open price$59.59

Volume

1.43M

Volume1.43M

52 Week high

$66.28

52 Week high$66.28

52 Week low

$49.26

52 Week low$49.26

Stock Snapshot

BioMarin(BMRN) stock is priced at $59.59, giving the company a market capitalization of 11.52B. It carries a P/E multiple of 43.78.

On 2026-07-18, BioMarin(BMRN) stock traded between a low of $59.40 and a high of $60.64. Shares are currently priced at $59.59, which is +0.3% above the low and -1.7% below the high.

BioMarin(BMRN) shares are trading with a volume of 1.43M, against a daily average of 1.42M.

In the last year, BioMarin(BMRN) shares hit a 52-week high of $66.28 and a 52-week low of $49.26.

BMRN News

Simply Wall St 1d

How FDA Review of VOXZOGO Full-Approval Data at BioMarin Has Changed Its Investment Story

BioMarin Pharmaceutical recently announced that the FDA accepted its supplemental New Drug Application to convert VOXZOGO’s accelerated approval in children wit...

TipRanks 3d

BioMarin price target raised to $76 from $75 at Citi

Citi analyst Eric Joseph raised the firm’s price target on BioMarin (BMRN) to $76 from $75 and keeps a Buy rating on the shares. The firm adjusted models in the...

Simply Wall St 3d

BioMarin Wins FDA Review For VOXZOGO Full Approval In Achondroplasia

FDA accepts BioMarin Pharmaceutical's supplemental New Drug Application for VOXZOGO for children with achondroplasia. Submission is based on extensive long-ter...

Analyst ratings

76%

of 29 ratings

Buy

75.9%

Hold

24.1%

Sell

More BMRN News

TipRanks 5d

Neutral Stance Maintained on BioMarin as Competitive Threats Offset VOXZOGO Progress; $50 Price Target Reaffirmed

BioMarin Pharmaceutical, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mitchell Kapoor from H.C. Wainwright reiterated a...

TipRanks 6d

BioMarin announces FDA accepts sNDA for full approval of Voxzogo

BioMarin (BMRN) Pharmaceutical announced that the U.S. FDA has accepted the company’s supplemental New Drug Application for Voxzogo for full approval in childre...

People also own

Based on the portfolios of people who own BMRN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.